• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

    27.61 -1.17 (-4.07%)
    Streaming Delayed Price Updated: 1:47 PM EDT, Jul 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Arcutis Biotherapeutics, Inc. - Common stock

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    News headline image
    FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗
    Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value. 
    Via The Motley Fool
    News headline image
    Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% ↗
    Via The Motley Fool
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price ↗
    Via Chartmill
    Arcutis Biotherapeutics (NASDAQ:ARQT) Beats Q1 Revenue Estimates but Posts Wider-Than-Expected Loss; Shares Slide ↗
    Via Chartmill
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Surpasses Q4 Estimates and Raises 2026 Sales Outlook ↗
    Via Chartmill
    News headline image
    FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status ↗
    Arcutis Biotherapeutics (NASDAQ:ARQT) executives said ZORYVE continues to post strong growth and outlined several regulatory and clinical catalysts expected over the next year, while emphasizing that... 
    Via MarketBeat
    News headline image
    Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
    This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
    Via The Motley Fool
    Topics Regulatory Compliance
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows Technical Breakout Setup ↗
    Via Chartmill
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows High-Growth Momentum and Strong Technical Setup ↗
    Via Chartmill
    News headline image
    New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis (ARQT) Q1 2026 Earnings Transcript ↗
    Arcutis (ARQT) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate ↗
    Arcutis Biotherapeutics (ARQT) combines strong earnings growth with a bullish technical setup, presenting a potential breakout opportunity for momentum investors. 
    Via Chartmill
    News headline image
    Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know ↗
    Focused on innovative dermatology treatments, this biopharma firm reported a notable insider sale amid a strong year for its shares. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Arcutis (ARQT) Q4 2025 Earnings Call Transcript ↗
    Arcutis (ARQT) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit ↗
    Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and atopic dermatitis. 
    Via The Motley Fool
    News headline image
    Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
    From Arcutis Biotherapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.